President Donald Trump has given generic-drug manufacturers a choice – add U.S. capacity within two years or face tariffs.
Writing on Truth Social, Trump framed the measure as one designed to "RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time." His schedule is precise – imported generics stay at a 0% tariff from Aug. 1, 2026, through July 31, 2028, before the rate climbs to 100% for one year and then to 200% from Aug. 1, 2029.
The approach differs from the administration's treatment of branded medicines.
Reuters reported that drugmakers secured tariff exemptions through pricing agreements or commitments to manufacture domestically.
However, generic producers have less room to bargain because a low-price business model leaves little cushion to absorb a levy of that magnitude.
